{"id":"florbetaben-bay94-9172","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1908906","moleculeType":"Small molecule","molecularWeight":"359.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Florbetaben is a PET tracer designed to visualize amyloid-beta accumulation in the brain by binding to amyloid plaques. The fluorine-18 radiolabel enables detection via PET imaging, allowing clinicians to assess amyloid burden in patients with cognitive impairment or suspected Alzheimer's disease. This diagnostic tool helps identify amyloid pathology that correlates with neurodegenerative disease progression.","oneSentence":"Florbetaben is a fluorine-18 labeled imaging agent that binds to amyloid-beta plaques in the brain for positron emission tomography (PET) detection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:45.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT01222351","phase":"NA","title":"Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-12","conditions":"Late Onset Alzheimer Disease","enrollment":161},{"nctId":"NCT01020838","phase":"PHASE3","title":"Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology","status":"COMPLETED","sponsor":"Life Molecular Imaging SA","startDate":"2009-11","conditions":"Alzheimer Disease","enrollment":218},{"nctId":"NCT00750282","phase":"PHASE2","title":"Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers","status":"COMPLETED","sponsor":"Life Molecular Imaging SA","startDate":"2008-08","conditions":"Alzheimer Disease, Amyloid Beta-Protein","enrollment":422},{"nctId":"NCT01138111","phase":"PHASE1","title":"Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients","status":"COMPLETED","sponsor":"Life Molecular Imaging SA","startDate":"2008-06","conditions":"Alzheimer Disease, Amyloid Beta-Protein","enrollment":45},{"nctId":"NCT00928304","phase":"PHASE2","title":"Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.","status":"COMPLETED","sponsor":"Life Molecular Imaging SA","startDate":"2009-06","conditions":"Down Syndrome, Amyloid Beta-protein","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Florbetaben (BAY94-9172)","genericName":"Florbetaben (BAY94-9172)","companyName":"Life Molecular Imaging SA","companyId":"life-molecular-imaging-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Florbetaben is a fluorine-18 labeled imaging agent that binds to amyloid-beta plaques in the brain for positron emission tomography (PET) detection. Used for Detection of amyloid-beta plaques in patients with cognitive impairment or suspected Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}